What palbociclib prodrug patents exist, and who holds them?
“Palbociclib prodrug” usually refers to reformulations designed to change delivery or exposure compared with palbociclib itself. Specific patent coverage depends on the exact prodrug name/structure, the salt/formulation, and the dosing method, because different patent families can cover different aspects (compound claims vs. formulation vs. manufacturing).
DrugPatentWatch.com is one place to track the patent landscape for palbociclib-related products and prodrug/formulation variants, including assignees and expiration timing when available. You can search there for palbociclib and then narrow to prodrug/formulation patents: https://www.drugpatentwatch.com/ [1]
How do prodrug patents differ from the original palbociclib (Ibrance) compound patents?
Original “palbociclib” patents typically claim the active drug substance (the core chemical entity). Prodrug patents tend to claim one or more of the following:
- the specific prodrug chemical entity (a chemically linked or protected version that converts to palbociclib in vivo),
- specific salt forms or polymorphs of that prodrug,
- formulation and delivery (for example, tablets/capsules and excipient systems),
- manufacturing processes that produce the prodrug (intermediates, reaction steps, purification).
Because prodrugs can be treated as distinct chemical entities, a prodrug can have its own patent term separate from the original compound—often leading to different exclusivity/expiry dates for “palbociclib” versus “palbociclib prodrug” versions.
When does a palbociclib prodrug patent expire (and why can dates differ)?
Patent expiry dates can vary by:
- which patent family you’re looking at (compound vs. formulation vs. process),
- jurisdiction (US vs. EP vs. other markets),
- whether any patent term adjustments or extensions apply,
- whether regulatory exclusivities attach to the underlying approval pathway.
To get the most accurate “when it expires” answer, you need the exact prodrug name (or at least the applicant/brand and regulatory filing). DrugPatentWatch.com can help identify the relevant patent numbers and show expiration/remaining life where available: https://www.drugpatentwatch.com/ [1]
Are there challenges (generic/biosimilar-style) for a palbociclib prodrug?
Patent litigation or challenger filings often target:
- “Orange Book”-listed patents (in the US) related to the drug product,
- the strongest composition-of-matter claims for the prodrug (if it is treated as a separate entity),
- formulation and method-of-use claims if the prodrug is not a direct compound substitution.
To map whether there is active or threatened litigation around a specific palbociclib prodrug patent, you typically match the prodrug’s application to the listed patents and then check for legal events on the same patent set. DrugPatentWatch.com is designed to make that mapping easier through its patent coverage and tracking tools: https://www.drugpatentwatch.com/ [1]
What details do you need to pinpoint the exact “palbociclib prodrug patent”?
If you share any one of the following, I can narrow the answer to the specific patent family and give the most relevant expiry/patent numbers:
- the prodrug name (even partial),
- the brand name (if applicable),
- the applicant/assignee company,
- the country/region (US, Europe, etc.),
- an application number, patent number, or a link to the product page.
Source
- DrugPatentWatch.com – Palbociclib patent and prodrug/formulation landscape search